Preliminary Scientific Program

Transcription

1 Preliminary Scientific Program ΠΑΡΑΣΚΕΥΗ 11 ΣΕΠΤΕΜΒΡΙΟΥ Welcome and Chair Remarks V. Georgoulias University of Crete Breast Cancer HER2/ER ER+ - HER2+ Chair: V. Barbounis Presenter 1: E. Saloustros Primary results, NRG Oncology/NSABP B-35: A clinical trial of anastrozole (A) versus tamoxifen (tam) in postmenopausal patients with DCIS undergoing lumpectomy plus radiotherapy. Title:PALOMA3: A double-blind, phase III trial of fulvestrant with or without palbociclib in pre- and post-menopausal women with hormone receptorpositive, HER2-negative metastatic breast cancer that progressed on prior endocrine therapy Presenter 2: E. Galani Title: Phase III, randomized study of trastuzumab emtansine (T-DM1) ± pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2- positive MBC: Primary results from the MARIANNE study. Title: Neratinib after adjuvant chemotherapy and trastuzumab in HER2- positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET) Discussant: D. Tryfonopoulos General Discussion Breast Cancer Triple Negative/Cytotoxics/Local Therapy Chair: Ch. Papadimitriou Presenter 1: N. Xenidis Title: Phase III trial of etirinotecan pegol (EP) versus Treatment of Physician s Choice (TPC) in patients (pts) with advanced breast cancer (abc) whose disease has progressed following anthracycline (A), taxane (T) and capecitabine (C): The BEACON study. Title: Results from a phase 2 study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC).

2 Presenter 2: M. Nikolaidi Title: Relationship of omission of adjuvant radiotherapy to outcomes of locoregional control and disease-free survival in patients with or without pcr after neoadjuvant chemotherapy for breast cancer: A meta-analysis on 3481 patients from the Gepar-trials. Title: Low-dose oral cyclophosphamide-methotrexate maintenance (CMM) for receptor-negative early breast cancer (BC). Title: The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast Discussant: D. Mavroudis General Discussion Coffee Break Melanoma Chair: D. Bafaloukos Presenter 1: A. Boutis Title: Efficacy and safety results from a phase III trial of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients (pts) with advanced melanoma (MEL) (CheckMate 067). Title: Long term follow up of survival in a randomised trial of wide or narrow excision margins in high risk primary melanoma Presenter 2: F. Stavridi Title: Overall survival in COMBI-d, a randomized, double-blinded, phase III study comparing the combination of dabrafenib and trametinib with dabrafenib and placebo as first-line therapy in patients (pts) with unresectable or metastatic BRAF V600E/K mutation-positive cutaneous melanoma. Title: Survival of SLNB-positive melanoma patients with and without complete lymph node dissection: A multicenter, randomized DECOG trial Discussant: TBC General Discussion Sarcoma Chair: I. Boukovinas Presenter: A. Laskarakis Discussant: TBC General Discussion

3 Patient and Survivor Care Chair: A. Christopoulou Presenter 1: TBC Title: Adjuvant denosumab in breast cancer: Results from 3,425 postmenopausal patients of the ABCSG-18 trial. Title: Phase III trials of anamorelin in patients with advanced non-small cell lung cancer (NSCLC) and cachexia (ROMANA 1 and 2). Title: CALGB (Alliance): A randomized phase III study of standard dosing vs. longer interval dosing of zoledronic acid in metastatic cancer Presenter 2: Ε. Maragouli Title: Long-term safety of fertility preservation by ovarian stimulation and concurrent aromatase inhibitor treatment in women with breast cancer. Title: Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial Discussant: TBD General Discussion D i n n e r ΣΑΒΒΑΤΟ 12 ΣΕΠΤΕΜΒΡΙΟΥ Gastrointestinal (Colorectal) Cancer Chair: P. Papakostas Presenter 1: Z. Saridaki Title: The survival benefit offered by the surgical management of low-grade ductal carcinoma in situ of the breast. Title: Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup (CLOCC). Title: SIRFLOX: Randomized phase III trial comparing first-line mfolfox6 ± bevacizumab (bev) versus mfolfox6 + selective internal radiation therapy (SIRT) ± bev in patients (pts) with metastatic colorectal cancer (mcrc) Presenter 2: M. Theochari Title: Vitamin D status and survival of metastatic colorectal cancer patients: Results from CALGB/SWOG (Alliance). Title: Impact of aspirin as secondary prevention in an unselected cohort of 25,644 patients with colorectal cancer: A population-based study.

4 Discussant: Th. Makatsoris General Discussion Gastrointestinal (Non-Colorectal) Cancer Chair: Ch. Panopoulos Presenter : K. Ploiarchopoulou Title: Phase III, randomized, double-blind, multicenter, placebo (P)-controlled trial of rilotumumab (R) plus epirubicin, cisplatin and capecitabine (ECX) as first-line therapy in patients (pts) with advanced MET-positive (pos) gastric or gastroesophageal junction (G/GEJ) cancer: RILOMET-1 study. Title: Relationship between PD-L1 expression and clinical outcomes in patients with advanced gastric cancer treated with the anti-pd-1 monoclonal antibody pembrolizumab (MK-3475) in KEYNOTE-012. Title: Randomized phase II study of everolimus (E) versus everolimus plus bevacizumab (E+B) in patients (Pts) with locally advanced or metastatic pancreatic neuroendocrine tumors (pnet), CALGB (Alliance) Discussant: Ch. Kourousis General Discussion Coffee Break Gynecologic Cancer Chair: Ch. Christofyllakis Presenter 1: TBD Title: A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P. Title: Results of ARIEL2: a Phase 2 trial to prospectively identify ovarian cancer patients likely to respond to rucaparib using tumor genetic analysis Presenter 2: I. Syrios Title: Avelumab (MSB C), an anti-pd-l1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: A phase Ib, openlabel expansion trial. Title: CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: An ECOG-ACRIN and NRG GOG study Discussant: E. Timotheadou General Discussion

5 Genitourinary Cancer Chair: D. Daliani Presenter 1: S. Stamatopoulou Title: Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT ). Title: A phase III protocol of androgen suppression (AS) and 3DCRT/IMRT versus AS and 3DCRT/IMRT followed by chemotherapy (CT) with docetaxel and prednisone for localized, high-risk prostate cancer (RTOG 0521). Title: Defining a molecular subclass of treatment resistant prostate cancer Presenter 2: G. Economopoulou Title: Interest of short hormonotherapy (HT) associated with radiotherapy (RT) as salvage treatment for biological relapse (BR) after radical prostatectomy (RP): Results of the GETUG-AFU 16 phase III randomized trial NCT Title: TROG and VCOG PR 01-03: The "timing of androgen deprivation therapy in prostate cancer patients with a rising PSA (TOAD)" collaborative randomised phase III trial Discussant: E. Bournakis Presenter 3: E. Lianos Title: First-line randomized phase II study of gemcitabine/cisplatin plus apatorsen or placebo in patients with advanced bladder cancer: The International Borealis-1 trial. Title: A phase II/III, double-blind, randomized trial comparing maintenance lapatinib versus placebo after first line chemotherapy in HER1/2 positive metastatic bladder cancer patients Presenter 4: V. Rizouli Title: Randomized phase II, three-arm trial of lenvatinib (LEN), everolimus (EVE), and LEN+EVE in patients (pts) with metastatic renal cell carcinoma (mrcc). Title: Final clinical results of a randomized phase II international trial of everolimus vs. sunitinib in patients with metastatic non-clear cell renal cell carcinoma (ASPEN) Discussant: A. Bamias General Discussion

6 Head and Neck Cancer Chair: A. Argyris Presenter 1: E. Douvelis Title: Elective versus therapeutic neck dissection in the clinically node negative early oral cancer: A randomised control trial (RCT). Title: Phase III randomized trial of standard fractionation radiotherapy (SFX) with concurrent cisplatin (CIS) versus accelerated fractionation radiotherapy (AFX) with panitumumab (PMab) in patients (pts) with locoregionally advanced squamous cell carcinoma of the head and neck (LA-SCCHN): NCIC Clinical Trials Group HN.6 trial. Title: Prognostic implication of persistent HPV16 DNA detection in oral rinses for HPV-positive oropharyngeal carcinoma Presenter 2: A. Tzovaras Title: Antitumor activity and safety of pembrolizumab in patients (pts) with advanced squamous cell carcinoma of the head and neck (SCCHN): Preliminary results from KEYNOTE-012 expansion cohort. Title: PET-NECK: A multi-centre, randomized, phase III, controlled trial (RCT) comparing PETCT guided active surveillance with planned neck dissection (ND) for locally advanced (N2/N3) nodal metastases (LANM) in patients with head and neck squamous cell cancer (HNSCC) treated with primary radical chemoradiotherapy (CRT) Discussant: I. Athanasiadis General Discussion Lunch Lung Cancer Non-Small Cell Lung Cancer: Metastatic Chair: E. Samantas Presenter 1: V. Karavassilis Title: NCCTG N0574 (Alliance): A phase III randomized trial of whole brain radiation therapy (WBRT) in addition to radiosurgery (SRS) in patients with 1 to 3 brain metastases. Title: Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-sq) non-small cell lung cancer (NSCLC).

7 Presenter 2: P. Katsaounis Title: Efficacy of rociletinib (CO-1686) in plasma-genotyped T790M-positive nonsmall cell lung cancer (NSCLC) patients (pts). Title: Whole brain radiotherapy for brain metastases from non-small lung cancer: Quality of life (QoL) and overall survival (OS) results from the UK Medical Research Council QUARTZ randomised clinical trial (ISRCTN ) Presenter 3: Ph. Koinis Title: Interim results of a phase II study of the BRAF inhibitor (BRAFi) dabrafenib (D) in combination with the MEK inhibitor trametinib (T) in patients (pts) with BRAF V600E mutated (mut) metastatic non-small cell lung cancer (NSCLC). Title: Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR) Discussant: S. Agelaki General Discussion Coffee Break Lung Cancer Non-Small Cell Local-Regional/Small Cell Chair: N. Kentepozidis Presenter 1: S. Peroukidis Title: Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC MAPS randomized phase 3 trial. Title: Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): Preliminary safety and efficacy results from KEYNOTE Presenter 2: S. Kaltsas Title: Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA Title: Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsnsclc). Title: Randomized phase III trial of customized adjuvant chemotherapy (CT) according BRCA-1 expression levels in patients with node positive resected nonsmall cell lung cancer (NSCLS) SCAT: A Spanish Lung Cancer Group trial (Eudract: ; NCTgov: ) Discussant: M. Vaslamatzis General Discussion

8 Educational Session: Tumor Immunology Chair: A. Kotsakis Presenter: M. Liontos General Discussion Developmental Therapeutics Chair: A. Psyrri Presenter 1: E. Kontopodis Title: Successful implementation of a novel trial model: The Signature program. Title: A pharmacokinetically (PK) and pharmacodynamically (PD) driven phase I trial of the pan-akt inhibitor AZD5363 with expansion cohorts in PIK3CA mutant breast and gynecological cancers Presenter 2: N. Diamantopoulos Title: Phase II multicenter proof of concept study of AZD4547 in FGFR amplified tumours. Title: A phase I study of PF (anti-4-1bb) + rituximab in patients with CD20+ NHL Discussant: A. Koutras Presenter 3: ΤΒD Title: Safety and efficacy of MEDI4736, an anti-pd-l1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Title: Efficacy based on tumor PD-L1 expression in KEYNOTE-002, a randomized comparison of pembrolizumab (pembro; MK-3475) versus chemotherapy in patients (pts) with ipilimumab-refractory (IPI-R) advanced melanoma (MEL) Discussant: J. Janinis General Discussion